FAR1

Fatty acyl-CoA reductase 1 · Q8WVX9 · FAR1 on Sugi Atlas →

0 patent compounds predicted against FAR1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to FAR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacogenomic Evaluation of Antihypertensive Responses PHASE4COMPLETED
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon PHASE4COMPLETED
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia PHASE3COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma PHASE2COMPLETED
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension PHASE2NOT_YET_RECRUITING
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Familial Partial Lipodystrophy Study nanCOMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women nanUNKNOWN
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Genes Involved in Lipid Disorders nanCOMPLETED
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile nanWITHDRAWN
Re-energize With Nutrition, Exercise and Weight Loss nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Genetic Origin of Lipid Disorders nanUNKNOWN
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
Sodium Transport: Genetics and Hypertension nanCOMPLETED
Genetic Epidemiology of Hypertriglyceridemia nanCOMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
Hepatic Energy Fluxes in NASH and NAS Patients nanACTIVE_NOT_RECRUITING
Androgens and NAFLD Longitudinal Cohort Study nanRECRUITING
Omics-based Predictors of NAFLD/Potential NASH nanUNKNOWN
Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy nanUNKNOWN
Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FAR1 binder may also engage these)

ProteinNameSimilarity
Q5R834 1.000 Q5R834 →
Q922J9 1.000 Q922J9 →
Q7ZXF5 1.000 Q7ZXF5 →
Q66H50 1.000 Q66H50 →
Q5ZM72 0.999 Q5ZM72 →
Q0P5J1 0.997 Q0P5J1 →
Q7TNT2 0.994 Q7TNT2 →
Q96K12 0.993 Q96K12 →
Q8MS59 0.992 Q8MS59 →
Q9LXN3 0.983 Q9LXN3 →
A1ZAI5 0.982 A1ZAI5 →
Q960W6 0.981 Q960W6 →
Q1PEI6 0.981 Q1PEI6 →
Q39152 0.980 Q39152 →
Q9XGY7 0.979 Q9XGY7 →
Q0WRB0 0.976 Q0WRB0 →
Q93ZB9 0.974 Q93ZB9 →
Q9FMQ9 0.970 Q9FMQ9 →
A1ZAI3 0.970 A1ZAI3 →
G7JEE5 0.968 G7JEE5 →
A0A059TC02 0.966 A0A059TC02 →
P0DKC5 0.965 P0DKC5 →
P0DKC6 0.965 P0DKC6 →
Q7T2D1 0.965 Q7T2D1 →
A5PJF6 0.964 A5PJF6 →
Q67477 0.964 Q67477 →
Q5XGF7 0.964 Q5XGF7 →
Q8HZT6 0.964 Q8HZT6 →
Q5M875 0.964 Q5M875 →
Q8IZV5 0.964 Q8IZV5 →